Lawrence T. Friedhoff
Chief Development Officer
Neurology
Axovant Sciences
Switzerland
Biography
Dr. Lawrence T. Friedhoff has served as Chief Development Officer of Axovant Sciences, Inc. since May 2015. He has a 30-year record of identifying promising drug candidates and managing all phases of their development, always with an eye toward fulfilling drug approval requirements. He has managed post-FDA-approval activities including marketing-related, safety surveillance and post-approval studies. He is currently Chief of Research and Development at Roivant Sciences, Inc. Previously, he held positions at Eisai, Squibb and Andrx Corporation. At Eisai, he led the drug development team for Aricept® (donepezil), the top-selling drug for Alzheimer’s disease in history, and the new drug approval team for AcipHex® (rabeprazole) for the treatment of heartburn. He is the author of the book New Drugs and author or co-author of many peer-reviewed publications in major scientific journals. He received an MD from New York University School of Medicine and a PhD in chemistry from Columbia University. He is a fellow of the American College of Physicians.
Research Interest
neurology, CNS drugs, Alzheimer’s disease and dementia, Balance Impairments, REM Sleep Behavior Disorder, pharmaceuticals, drugs.
